Decentralized clinical trials: a practical operating guide

Decentralized clinical trials move some trial activities away from traditional research sites. FDA's September 2024 guidance describes elements such as telehealth, home visits, and activities carried out by local healthcare providers. A study can combine these with conventional site visits.

The useful question is not whether a study sounds decentralized. It is whether each activity can be carried out appropriately, with clear clinical oversight, reliable information, and a workable experience for participants. Moving an activity changes the workflow; it does not remove the responsibility to perform it properly.

Decide which activities can move

Begin with the protocol schedule. For each activity, document the setting, qualifications, equipment, timing, information produced, and escalation route. Some activities may be suitable for remote delivery; others require facilities, observation, or procedures that make an in-person setting necessary.

A video appointment and a home procedure are different operating models. Do not assume one vendor or workflow can support both. Review the proposed approach with the sponsor and the responsible clinical and regulatory teams before presenting it as an available option.

Draw the responsibility map

Identify who schedules the activity, confirms readiness, performs it, documents the result, reviews the information, and responds to a concern. Then identify backup coverage. A handoff is incomplete if both organizations believe the other will contact the participant.

For example, a home visit plan needs an answer for a staff absence, an inaccessible address, missing supplies, and an abnormal finding. These are planning scenarios, not statements about a particular study's permitted procedures. The clinical response must follow that study's actual instructions.

Examine the participant's full workload

Remote activities can reduce travel while creating other demands. A participant may need reliable connectivity, a private space, device setup, charging, troubleshooting, or time available for a visiting professional.

Ask what happens when the technology does not work or a person cannot use the proposed format. Explain available support and alternatives accurately. Do not describe remote participation as automatically easier or more inclusive for every person.

The visit planning guide can help teams discuss the total commitment, including activities that happen at home.

Treat information flow as part of the visit

Decide where information is first recorded, how it reaches the responsible reviewer, and how the team recognizes a missing or delayed record. Confirm which system holds the authoritative record and how corrections are handled.

Test the workflow with synthetic records before using participant information. Include an interrupted connection, an incomplete activity, and a result that needs timely clinical attention. A successful upload is not evidence that someone reviewed the information.

Compare decentralized clinical trial companies by responsibility

The phrase “decentralized clinical trial company” can describe a platform provider, a home-service provider, a coordinating organization, or a combination. Start a comparison by asking which responsibilities each proposal actually covers.

Request a written scope that identifies locations served, staffing model, support hours, subcontractors, scheduling commitments, information exchange, escalation, training, and exit arrangements. Ask the vendor to walk through your exception scenarios, not only its preferred demonstration.

Evaluate total cost at the activity level. Include setup, travel or service charges, cancellations, equipment, integrations, support, and changes in volume. A per-visit price is difficult to compare if one proposal excludes coordination that another includes.

Pilot a defined workflow

Choose a bounded activity and state what must be demonstrated before expanding it. Useful measures include missed handoffs, incomplete records, participant support requests, and the time needed to resolve exceptions. Interpret results alongside the clinical and operational context.

FDA's guidance is a primary reference for the U.S. regulatory discussion; local law, the protocol, and the responsibilities of the study's organizations still require specific assessment. For broader system questions, use the clinical trial software evaluation guide.